MS Drug Ocrelizumab (Ocrevus) Approved in Europe MS Drug Ocrelizumab (Ocrevus) Approved in Europe

The European Commission clears the anti-CD20 monoclonal antibody for adults with relapsing multiple sclerosis and early primary progressive multiple sclerosis.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Related Links:

Clinical trial compares stem cell transplantation with existing disease-modifying therapies and finds that the former is more effective at slowing down MS.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news
ConclusionOur 4-week program reduced some aspects of fatigue and improved some aspects of quality of life in a small group of ambulatory and non-ambulatory individuals with MS. Good feasibility and significant positive changes from baseline warrant further exploratory work.Trial registrationName of the registry: The Impact of Exercise Training on Living Quality in Multiple Sclerosis. Registration: The study was registered atwww.clinicaltrial.gov on July 14, 2017. First participant enrollment: August 28, 2017. URL: 602-01/17-01-147; Trial registration ID: NTC03222596.
Source: Neurological Sciences - Category: Neurology Source Type: research
Condition:   Multiple Sclerosis Interventions:   Behavioral: Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS);   Behavioral: BIPAMS + Diet Sponsor:   University of Alabama at Birmingham Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Sclerosis Interventions:   Other: myBETAapp;   Other: PEAK;   Drug: Betaferon, BAY 86-5046;   Device: BETACONNECT Sponsor:   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Sclerosis Interventions:   Behavioral: Behavioral Intervention for Physical Activity in Multiple Sclerosis (BIPAMS);   Behavioral: BIPAMS + Diet Sponsor:   University of Alabama at Birmingham Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Multiple Sclerosis Interventions:   Other: myBETAapp;   Other: PEAK;   Drug: Betaferon, BAY 86-5046;   Device: BETACONNECT Sponsor:   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: In lesions with a reduction of the ADC sodium levels are near normal and precede signs of BBB breakdown. These findings suggest a relatively preserved tissue structure in this early phase of lesion evolution
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
In conclusion, our study established that the genetic ancestry of MS-associated alleles is complex and implicated that difference in MS prevalence could be explained by the ancestry of MS-associated alleles.
Source: PLoS Genetics - Category: Genetics & Stem Cells Authors: Source Type: research
Demyelination, axonal loss and failure of tissue repair characterize MS lesions. Bone morphogenetic proteins (BMPs) signaling is associated with remyelination failure. Coco is one of the BMP antagonists. We found reduced Coco serum levels in relapsing-remitting MS (RR-MS) and primary progressive MS (PP-MS) patients compared to matched healthy controls (HC) and patients with rheumatoid arthritis. Exposure of P19 cells, in the presence of retinoic acid, BMP-2, or BMP-4 to Coco, at average sera level of MS patients failed to induce neuronal phenotype, in contrast to the average sera level of HC.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Tags: Short Communication Source Type: research
Multiple sclerosis is a chronic incapacitating disease of the central nervous system, it has been reported that the disturbance in the development and function of Treg subpopulations is associated with the disability status in the RRMS. Accordingly, in the current study, the objective was to specify nanocurcumin effects on Treg cells frequency, and function in patients with RRMS.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Source Type: research
More News: Brain | Health | Multiple Sclerosis | Neurology | Neurosurgery